Edition:
India

Catabasis Pharmaceuticals Inc (CATB.OQ)

CATB.OQ on NASDAQ Stock Exchange Global Market

6.00USD
20 Sep 2019
Change (% chg)

$-0.05 (-0.83%)
Prev Close
$6.05
Open
$6.07
Day's High
$6.33
Day's Low
$5.99
Volume
63,967
Avg. Vol
18,447
52-wk High
$9.76
52-wk Low
$3.60

Latest Key Developments (Source: Significant Developments)

Catabasis Pharmaceuticals Inc Qtrly Loss Per Share $0.62
Tuesday, 14 May 2019 

May 14 (Reuters) - Catabasis Pharmaceuticals Inc ::QTRLY LOSS PER SHARE $0.62.CATABASIS PHARMACEUTICALS - AS OF MARCH 31, 2019, HAD AVAILABLE CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $51.7 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.70 -- REFINITIV IBES DATA.  Full Article

Catabasis Pharma Reports Q1 Loss Per Share Of $0.62
Tuesday, 14 May 2019 

May 14 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q1 LOSS PER SHARE $0.62.Q1 EARNINGS PER SHARE ESTIMATE $-0.70 -- REFINITIV IBES DATA.AS OF MARCH 31, 2019, CATABASIS HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $51.7 MILLION.  Full Article

Catabasis Pharmaceuticals Announces Reverse Stock Split
Monday, 24 Dec 2018 

Dec 24 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT.CATABASIS PHARMACEUTICALS - WILL EFFECT A ONE-FOR-TEN REVERSE STOCK SPLIT OF ITS COMMON STOCK THAT WILL BE EFFECTIVE ON DECEMBER 28, 2018..  Full Article

Catabasis Pharmaceuticals Q3 Loss Per Share $0.08
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q3 LOSS PER SHARE $0.08.Q3 EARNINGS PER SHARE VIEW $-0.13 -- THOMSON REUTERS I/B/E/S.AT QUARTER END, CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $43.2 MILLION, VERSUS $49.9 MILLION AS OF JUNE 30, 2018.  Full Article

Catabasis Pharmaceuticals Inc - Collaboration with university of Texas Southwestern
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS INC - COLLABORATION WITH UNIVERSITY OF TEXAS SOUTHWESTERN.CATABASIS PHARMACEUTICALS -COLLABORATION TO EXPLORE POTENTIAL BENEFITS OF EDASALONEXENT ON CARDIAC FUNCTION IN DUCHENNE , BECKER MUSCULAR DYSTROPHIES.CATABASIS PHARMACEUTICALS INC - RESULTS ARE EXPECTED IN SECOND HALF OF 2019.  Full Article

Catabasis Pharmaceuticals Reports Q2 Loss Per Share $0.20
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q2 LOSS PER SHARE $0.20.Q2 EARNINGS PER SHARE VIEW $-0.23 -- THOMSON REUTERS I/B/E/S.AS OF JUNE 30, 2018, HAD CASH, CASH EQUIVALENTS OF $49.9 MILLION, COMPARED TO $17.0 MILLION AS OF MARCH 31, 2018.BASED ON CO'S CURRENT OPERATING PLAN, BELIEVES IT HAS SUFFICIENT CASH TO FUND OPERATIONS INTO Q2 2020.  Full Article

Catabasis Pharmaceuticals Presents New Edasalonexent Data
Thursday, 26 Apr 2018 

April 25 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS PRESENTS NEW EDASALONEXENT DATA SHOWING SIGNIFICANTLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION AS MEASURED BY MRI THROUGH ONE YEAR OF TREATMENT.CATABASIS PHARMACEUTICALS INC - STATISTICALLY SIGNIFICANT IMPROVEMENTS IN MRI T2 RATE OF CHANGE.  Full Article

Catabasis Pharma Aligns Resources To Focus On Lead Program Edasalonexent
Wednesday, 18 Apr 2018 

April 17 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS ALIGNS RESOURCES TO FOCUS ON LEAD PROGRAM EDASALONEXENT FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY.CATABASIS PHARMACEUTICALS INC - STRATEGIC CORPORATE RESTRUCTURING SUPPORTS GOAL OF ADVANCING EDASALONEXENT TOWARDS POTENTIAL REGISTRATION.CATABASIS PHARMACEUTICALS INC - RESTRUCTURING WILL REDUCE COMPANY'S WORKFORCE BY APPROXIMATELY 42%.CATABASIS PHARMACEUTICALS INC - ESTIMATES ANNUALIZED SAVINGS OF APPROXIMATELY $3.3 MILLION IN PERSONNEL-RELATED COSTS.CATABASIS PHARMACEUTICALS INC - ESTIMATED ONE-TIME SEVERANCE AND RELATED COSTS OF APPROXIMATELY $1.0 MILLION IN Q2 OF 2018.  Full Article

Clarus Lifesciences II Lp Reports A 6.92 Pct Stake In Catabasis Pharmaceuticals As Of March 22
Thursday, 5 Apr 2018 

April 4 (Reuters) - Catabasis Pharmaceuticals Inc ::CLARUS LIFESCIENCES II LP REPORTS A 6.92 PCT STAKE IN CATABASIS PHARMACEUTICALS INC <<>> AS OF MARCH 22 - SEC FILING .CLARUS LIFESCIENCES II LP PREVIOUSLY REPORTED A 11.92 PERCENT STAKE IN CATABASIS PHARMACEUTICALS AS OF OCT. 31, 2017.  Full Article

Catabasis Pharmaceuticals Reports Q4 Loss Per Share $0.24
Friday, 16 Mar 2018 

March 15 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q4 LOSS PER SHARE $0.24.Q4 REVENUE $300,000.Q4 EARNINGS PER SHARE VIEW $-0.31 -- THOMSON REUTERS I/B/E/S.CATABASIS PHARMACEUTICALS - PLANS TO INITIATE A GLOBAL PHASE 3 TRIAL WITH EDASALONEXENT IN PATIENTS WITH DMD REGARDLESS OF MUTATION TYPE IN H1 2018.  Full Article